Pfizer Quality Improvement Request for Proposals: Optimizing RSV Diagnosis by Improving Detection in Hospitalized Adults
Pfizer's grant funds projects to improve hospital detection and reporting of RSV in adults through sustainable, system-level quality improvements and adoption of evidence-based diagnostic practices.
Funder: Pfizer Inc.
Due Dates: June 22, 2026 (Submission Deadline; applications due by 23:59 EST)
Funding Amounts: Up to $50,000 per project; total program budget $350,000; project duration up to 12 months
Summary: Supports quality improvement projects to enhance timely, guideline-based RSV detection in hospitalized adults through sustainable, system-level changes.
Key Information: Only organizations in select European countries and Israel are eligible; late applications will not be reviewed.
Description
This competitive quality improvement (QI) grant program, offered by Pfizer, seeks proposals to implement sustainable, system-level changes to improve the detection of respiratory syncytial virus (RSV) in adult patients admitted to emergency departments or hospitalized with respiratory symptoms. The goal is to translate existing evidence on RSV diagnostics into local practice by strengthening testing pathways, raising clinical awareness, and improving reporting mechanisms. Projects should focus on measurable, sustainable improvements in RSV testing, reporting, and resource utilization in hospital settings. Multidisciplinary collaboration and initiatives that demonstrate clear system changes and measurable patient care impacts are highly encouraged.
